Current Antidiabetic Therapies and Mechanisms

Metabolic Syndrome: Underlying Mechanisms and Drug Therapies

Volumn , Issue , 2011, Pages 253-278

  Wang, Minghan ^a  

^a AMGEN INC   (United States)

Author keywords

Current antidiabetic therapies and mechanisms metabolic syndrome, cluster of metabolic disorders, and dyslipidemia; Future strategies of antidiabetic therapies monotherapy versus combination therapy; Sulfonylureas (SUs) and glinides Sus, a group of insulin secretagogues

Indexed keywords

EID: 84886159916     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470910016.ch10     Document Type: Chapter

References (111)

1. ETGEN, G.J., JR., C.M. WILSON, J. JENSEN, S.W. CUSHMAN, and J.L. IVY. 1996. Glucose transport and cell surface GLUT-4 protein in skeletal muscle of the obese Zucker rat. Am J Physiol Endocrinol Metab 271:E294-E301.
2. ZIERATH, J.R., L. HE, A. GUMA, E. ODEGOARD WAHLSTROM, A. KLIP, and H. WALLBERG-HENRIKSSON. 1996. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189.
3. KOISTINEN, H.A., D. GALUSKA, A.V. CHIBALIN, J.YANG, J.R. ZIERATH, G.D. HOLMAN, and H.WALLBERGHENRIKSSON. 2003. 5-Amino-imidazole carboxamide riboside increases glucose transport and cellsurface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 52:1066-1072.
4. MUSI, N., N. FUJII, M.F. HIRSHMAN, I. EKBERG, S. FROBERG, O. LJUNGQVIST, A. THORELL, and L.J. GOODYEAR. 2001. AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes 50:921-927.
5. FUNAI, K., and G.D. CARTEE. 2009. Inhibition of contraction-stimulated AMP-activated protein kinase inhibits contraction-stimulated increases in PAS-TBC1D1 and glucose transport without altering PAS-AS160 in rat skeletal muscle. Diabetes 58:1096-1104.
6. FRIEDMAN, J.E., W.M. SHERMAN, M.J. REED, C.W. ELTON, and G.L. DOHM. 1990. Exercise training increases glucose transporter protein GLUT-4 in skeletal muscle of obese Zucker (fa/fa) rats. FEBS Lett 268:13-16.
7. O'GORMAN, D.J., H.K. KARLSSON, S. MCQUAID, O. YOUSIF, Y. RAHMAN, D. GASPARRO, S. GLUND, A.V. CHIBALIN, J.R. ZIERATH, and J.J. NOLAN. 2006. Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes. Diabetologia 49:2983-2992.
8. DOHM, G.L. 2002. Invited review. Regulation of skeletal muscle GLUT-4 expression by exercise. J Appl Physiol 93:782-787.
9. IGLESIAS, M.A., J.M. YE, G. FRANGIOUDAKIS, A.K. SAHA, E. TOMAS, N.B. RUDERMAN, G.J. COONEY, and E.W. KRAEGEN. 2002. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 51:2886-2894.
10. LUCIANO, E., E.M. CARNEIRO, C.R. CARVALHO, J.B. CARVALHEIRA, S.B. PERES, M.A. REIS, M.J. SAAD, A.C. BOSCHERO, and L.A. VELLOSO. 2002. Endurance training improves responsiveness to insulin and modulates insulin signal transduction through the phosphatidylinositol 3-kinase/Akt-1 pathway. Eur J Endocrinol 147:149-157.
11. ABU-ELHEIGA, L., M.M. MATZUK, K.A. ABO-HASHEMA, and S.J. WAKIL. 2001. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science 291:2613-2616.
12. HOUMARD, J.A., C.J. TANNER, C. YU, P.G. CUNNINGHAM, W.J. PORIES, K.G. MACDONALD, and G.I. SHULMAN. 2002. Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl- CoAs in morbidly obese subjects. Diabetes 51:2959-2963.
13. KIM, J.K., J.J. FILLMORE, M.J. SUNSHINE,B.ALBRECHT, T.HIGASHIMORI,D.W.KIM, Z.X.LIU,T.J. SOOS,G. W. CLINE, W.R. O'BRIEN, D.R. LITTMAN, and G.I. SHULMAN. 2004. PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823-827.
14. BEFROY, D.E., K.F. PETERSEN, S. DUFOUR, G.F. MASON, D.L. ROTHMAN, and G.I. SHULMAN. 2008. Increased substrate oxidation and mitochondrial uncoupling in skeletal muscle of endurance-trained individuals. Proc Natl Acad Sci USA 105:16701-16706.
15. PAN, X.R., G.W. LI, Y.H. HU, J.X.WANG,W.Y. YANG, Z.X. AN, Z.X. HU, J.LIN, J.Z. XIAO, H.B. CAO, P. A. LIU, X.G. JIANG, Y.Y. JIANG, J.P.WANG, H.ZHENG, H.ZHANG, P.H. BENNETT, and B.V.HOWARD. 1997. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544.
16. UUSITUPA, M., A. LOUHERANTA, J. LINDSTROM, T. VALLE, J. SUNDVALL, J. ERIKSSON, and J. TUOMILEHTO. 2000. The Finnish Diabetes Prevention Study. Br J Nutr 83(Suppl 1): S137-S142.
17. KNOWLER,W.C., E. BARRETT-CONNOR, S.E. FOWLER, R.F. HAMMAN, J.M. LACHIN, E.A.WALKER, and D. M. NATHAN. 2002. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403.
18. GOLDBERG, R.B., M. TEMPROSA, S. HAFFNER, T.J. ORCHARD, R.E. RATNER, S.E. FOWLER, K.MATHER, S. MARCOVINA, C. SAUDEK, M.J. MATULIK, and D. PRICE. 2009. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care 32:726-732.
19. MAYFIELD, J.A., and R.D.WHITE. 2004. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 70:489-500.
20. UK, Prospective Diabetes Study, Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853.
21. OHKUBO, Y., H. KISHIKAWA, E.ARAKI, T. MIYATA, S. ISAMI, S. MOTOYOSHI, Y. KOJIMA, N. FURUYOSHI, and M. SHICHIRI. 1995. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103-117.
22. BAILEY, C.J. 1992. Biguanides and NIDDM. Diabetes Care 15:755-772.
23. MISBIN, R.I., L. GREEN, B.V. STADEL, J.L. GUERIGUIAN, A. GUBBI, and G.A. FLEMING. 1998. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265-266.
24. UK, Prospective Diabetes Study Group. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34).UKProspective Diabetes Study (UKPDS) Group. Lancet 352:854-865.
25. JONES, K.L., S. ARSLANIAN, V.A. PETEROKOVA, J.S. PARK, and M.J. TOMLINSON. 2002. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 25:89-94.
26. GARBER, A.J., T.G. DUNCAN, A.M. GOODMAN, D.J.MILLS, and J.L. ROHLF. 1997. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103:491-497.
27. STUMVOLL, M., N. NURJHAN, G. PERRIELLO, G. DAILEY, and J.E. GERICH. 1995. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554.
28. HUNDAL, R.S., M. KRSSAK, S. DUFOUR, D. LAURENT, V. LEBON, V. CHANDRAMOULI, S.E. INZUCCHI, W.C. SCHUMANN, K.F. PETERSEN, B.R. LANDAU, and G.I. SHULMAN. 2000. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069.
29. OWEN, M.R., E. DORAN, and A.P. HALESTRAP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3): 607-614.
30. ZHOU, G., R.MYERS,Y. LI,Y. CHEN,X. SHEN, J. FENYK-MELODY,M.WU, J.VENTRE, T.DOEBBER, N.FUJII, N. MUSI, M.F. HIRSHMAN, L.J. GOODYEAR, and D.E. MOLLER. 2001. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174.
31. HE, L., A. SABET, S. DJEDJOS, R. MILLER, X. SUN, M.A. HUSSAIN, S. RADOVICK, and F.E. WONDISFORD. 2009. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137:635-646.
32. KOO, S.H., L. FLECHNER, L.QI,X.ZHANG, R.A. SCREATON, S. JEFFRIES, S.HEDRICK,W.XU, F. BOUSSOUAR, P. BRINDLE, H. TAKEMORI, and M.MONTMINY. 2005. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109-1111.
33. GALUSKA, D., L.A. NOLTE, J.R. ZIERATH, and H.WALLBERG-HENRIKSSON. 1994. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 37:826-832.
34. SHU,Y., S.A. SHEARDOWN,C.BROWN, R.P.OWEN, S.ZHANG, R.A.CASTRO, A.G. IANCULESCU, L.YUE, J.C. LO, E.G. BURCHARD, C.M. BRETT, and K.M. GIACOMINI. 2007. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117:1422-1431.
35. BARNETT, D., J.G. CRAIG, D.S. ROBINSON, and M.P. ROGERS. 1977. Effect of clofibrate on glucose tolerance in maturity onset diabetes. Br J Clin Pharmacol 4:455-458.
36. MURPHY, E.J., T.J. DAVERN, A.O. SHAKIL, L. SHICK, U.MASHARANI, H. CHOW, C. FREISE,W.M. LEE, and N.M. BASS. 2000. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 45:549-553.
37. KAHN, S.E., B. ZINMAN, J.M. LACHIN, S.M. HAFFNER, W.H. HERMAN, R.R. HOLMAN, B.G. KRAVITZ, D. YU, M.A. HEISE, R.P. AFTRING, and G. VIBERTI. 2008. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 31:845-851.
38. TAKADA, I., A.P. KOUZMENKO, and S. KATO. 2009. Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies. Expert Opin Ther Targets 13:593-603.
39. BERG, A.H., T.P. COMBS, X. DU,M. BROWNLEE, and P.E. SCHERER. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 7:947-953.
40. MAEDA, N., M. TAKAHASHI, T. FUNAHASHI, S. KIHARA, H. NISHIZAWA, K. KISHIDA, H. NAGARETANI, M. MATSUDA, R. KOMURO, N. OUCHI, H. KURIYAMA, K. HOTTA, T. NAKAMURA, I. SHIMOMURA, and Y. MATSUZAWA. 2001. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099.
41. STEPPAN, C.M., S.T. BAILEY, S. BHAT, E.J. BROWN, R.R. BANERJEE, C.M. WRIGHT, H.R. PATEL, R.S. AHIMA, and M.A. LAZAR. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-312.
42. KALLEN, C.B., and M.A. LAZAR. 1996. Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes. Proc Natl Acad Sci USA 93:5793-5796.
43. CHAO, L., B.MARCUS-SAMUELS, M.M.MASON, J.MOITRA, C. VINSON, E. ARIOGLU, O. GAVRILOVA, and M. L. REITMAN. 2000. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 106:1221-1228.
44. LEBOVITZ, H.E., J.F. DOLE, R. PATWARDHAN, E.B. RAPPAPORT, and M.I. FREED 2001. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288.
45. PHILLIPS, L.S., G. GRUNBERGER, E. MILLER, R. PATWARDHAN, E.B. RAPPAPORT, and A. SALZMAN. 2001. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24:308-315.
46. WAGSTAFF, A.J., and K.L. GOA. 2002. Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus. Drugs 62:1805-1837.
47. ARONOFF, S., S. ROSENBLATT, S. BRAITHWAITE, J.W. EGAN, A.L. MATHISEN, and R.L. SCHNEIDER. 2000. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611.
48. XIANG, A.H., R.K. PETERS, S.L. KJOS, A. MARROQUIN, J. GOICO, C. OCHOA, M. KAWAKUBO, and T.A. BUCHANAN. 2006. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 55:517-522.
49. BUCHANAN, T.A., A.H. XIANG, R.K. PETERS, S.L. KJOS, A.MARROQUIN, J. GOICO, C. OCHOA, S. TAN, K. BERKOWITZ, H.N. HODIS, and S.P. AZEN. 2002. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803.
50. GERSTEIN, H.C., S.YUSUF, J. BOSCH, J.POGUE, P. SHERIDAN, N.DINCCAG,M.HANEFELD, B. HOOGWERF,M. LAAKSO, V. MOHAN, J. SHAW, B. ZINMAN, and R.R. HOLMAN. 2006. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368:1096-1105.
51. DE RIVAS, B., M. LUQUE, N. MARTELL, C. FERNANDEZ, and A. FERNANDEZ-CRUZ. 2007. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. J Clin Hypertens (Greenwich) 9:530-537.
52. SARAFIDIS, P.A., A.N. LASARIDIS, P.M. NILSSON, E.M. PAGKALOS, A.D. HITOGLOU-MAKEDOU, C.I. PLIAKOS, K.A. KAZAKOS, J.G. YOVOS, P.E. ZEBEKAKIS, I.M. TZIOLAS, and A.N. TOURKANTONIS. 2004. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 22:1769-1777.
53. KOTCHEN, T.A., H.Y. ZHANG, S. REDDY, and R.G. HOFFMANN. 1996. Effect of pioglitazone on vascular reactivity in vivo and in vitro. Am J Physiol Regul Integr Comp Physiol 270:R660-R666.
54. HSUEH,W.A., S. JACKSON, and R.E. LAW. 2001. Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes. Diabetes Care 24:392-397.
55. HORTON, E.S., F.WHITEHOUSE, M.N.GHAZZI, T.C.VENABLE, andR.W.WHITCOMB. 1998. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21:1462-1469.
56. FONSECA, V., J. ROSENSTOCK, R. PATWARDHAN, and A. SALZMAN. 2000. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695-1702.
57. BOYLE, P.J., A.B. KING, L. OLANSKY, A.MARCHETTI, H. LAU, R. MAGAR, and J.MARTIN. 2002. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective reviewof randomly selected medical records. Clin Ther 24:378-396.
58. KHAN, M.A., J.V. ST PETER, and J.L. XUE. 2002. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes whowere previously treated with troglitazone. Diabetes Care 25:708-711.
59. KING, A.B. 2000. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 23:557.
60. LACIVITA, K.A., and G. VILLARREAL. 2002. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 18:363-370.
61. VANWIJK, J.P., E.J. DE KONING, E.P.MARTENS, and T.J. RABELINK. 2003. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1744-1749.
62. PETRAZZI, L., D.GRASSI, L. POLIDORO,A.D'AURELIO,G.CROCE,G. PROPERZI, S. TIBERTI,G.DESIDERI, and C. FERRI. 2008. Cardiovascular risk and cardiometabolic protection: role of glitazones. J Nephrol 21:826-835.
63. RIZZO, M., E.R. CHRIST, G.B. RINI, G.A. SPINAS, and K. BERNEIS. 2008. The differential effects of thiazolidinediones on atherogenic dyslipidemia in type 2 diabetes: what is the clinical significance? Expert Opin Pharmacother 9:2295-2303.
64. DORMANDY, J.A., B.CHARBONNEL, D.J. ECKLAND, E. ERDMANN,M.MASSI-BENEDETTI, I.K.MOULES, A.M. SKENE, M.H. TAN, P.J. LEFEBVRE, G.D. MURRAY, E. STANDL, R.G. WILCOX, L. WILHELMSEN, J. BETTERIDGE, K. BIRKELAND, A. GOLAY, R.J. HEINE, L. KORANYI, M. LAAKSO, M. MOKAN, A. NORKUS, V. PIRAGS, T.PODAR, A. SCHEEN,W. SCHERBAUM, G.SCHERNTHANER, O.SCHMITZ, J.SKRHA, U. SMITH, and J. TATON. 2005. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289.
65. NISSEN, S.E., and K. WOLSKI. 2007. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457-2471.
66. BRACKEN, M.B. 2007. Rosiglitazone and cardiovascular risk.NEngl J Med 357: 937-938; author reply 939-940.
67. MANNUCCI, E., M.MONAMI, and N.MARCHIONNI. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med 357: 938; author reply 939-940.
68. DIAMOND, G.A., and S. KAUL. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med 357: 938-939; author reply 939-940.
69. BRETT, A.S. 2007. Rosiglitazone and cardiovascular risk. N Engl J Med 357: 939; author reply 939-940.
70. HOME, P.D., S.J. POCOCK, H. BECK-NIELSEN, P.S. CURTIS, R. GOMIS, M. HANEFELD, N.P. JONES, M. KOMAJDA, and J.J. MCMURRAY. 2009. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373:2125-2135.
71. ZIMMERMAN, B.R. 1997. Sulfonylureas. Endocrinol Metab Clin North Am 26:511-522.
72. KLEPZIG, H., G. KOBER, C. MATTER, H.LUUS, H. SCHNEIDER, K.H. BOEDEKER,W. KIOWSKI, F.W. AMANN, D. GRUBER, S. HARRIS, andW. BURGER. 1999. Sulfonylureas and ischaemic preconditioning; a doubleblind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20:439-446.
73. GOLDNER, M.G., G.L. KNATTERUD, and T.E. PROUT. 1971. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 218:1400-1410.
74. KILO, C., J.P. MILLER, and J.R. WILLIAMSON. 1980. The crux of the UGDP. Spurious results and biologically inappropriate data analysis. Diabetologia 18:179-185.
75. SIMONSON, D.C., E. FERRANNINI, S. BEVILACQUA, D. SMITH, E. BARRETT, R. CARLSON, and R.A. DEFRONZO. 1984. Mechanism of improvement in glucose metabolismafter chronic glyburide therapy. Diabetes 33:838-845.
76. ROSENSTOCK, J., E. SAMOLS, D.B. MUCHMORE, and J. SCHNEIDER. 1996. Glimepiride, a new once-daily sulfonylurea.Adouble-blind placebo-controlled study ofNIDDMpatients. Glimepiride Study Group. Diabetes Care 19:1194-1199.
77. KAHN, S.E., S.M. HAFFNER, M.A. HEISE,W.H. HERMAN, R.R. HOLMAN, N.P. JONES, B.G. KRAVITZ, J.M. LACHIN, M.C. O'NEILL, B. ZINMAN, and G. VIBERTI. 2006. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427-2443.
78. MARBURY, T.,W.C. HUANG, P. STRANGE, and H. LEBOVITZ. 1999. Repaglinide versus glyburide: a oneyear comparison trial. Diabetes Res Clin Pract 43:155-166.
79. LANDGRAF, R., H.J. BILO, and P.G. MULLER. 1999. A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165-171.
80. WOLFFENBUTTEL, B.H., and R. LANDGRAF. 1999. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. Diabetes Care 22:463-467.
81. CLISSOLD, S.P., and C. EDWARDS. 1988. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243.
82. CHIASSON, J.L., R.G. JOSSE, J.A. HUNT, C. PALMASON, N.W. RODGER, S.A. ROSS, E.A. RYAN, M.H. TAN, and T.M.WOLEVER. 1994. The efficacy of acarbose in the treatment of patients with non-insulindependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928-935
83. CONIFF, R.F., J.A. SHAPIRO, D. ROBBINS, R. KLEINFIELD, T.B. SEATON, P. BEISSWENGER, and J.B.MCGILL. 1995. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care 18:817-824.
84. MENTLEIN, R. 1999. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
85. WEYER, C., D.G. MAGGS, A.A. YOUNG, and O.G. KOLTERMAN. 2001. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 7:1353-1373.
86. REDA, T.K., A. GELIEBTER, and F.X. PI-SUNYER. 2002. Amylin, food intake, and obesity. Obes Res 10:1087-1091.
87. GEDULIN, B.R., T.J. RINK, and A.A. YOUNG. 1997. Dose-response for glucagonostatic effect of amylin in rats. Metabolism 46:67-70.
88. YOUNG, A.A., B. GEDULIN, W. VINE, A. PERCY, and T.J. RINK. 1995. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia 38:642-648.
89. American Diabetes Association. 1998. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 21:1551-1559.
90. Diabetes Atherosclerosis Intervention Study Group. 2001. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910.
91. COLHOUN, H.M., D.J. BETTERIDGE, P.N. DURRINGTON, G.A. HITMAN, H.A. NEIL, S.J. LIVINGSTONE, M.J. THOMASON, and J.H. FULLER. 2005. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia 48:2482-2485.
92. ARCA, M. 2007. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. Drugs 67(Suppl 1): 43-54.
93. VAN VENROOIJ, F.V., M.A. VAN DE REE, M.L. BOTS, R.P. STOLK, M.V. HUISMAN, and J.D. BANGA. 2002. Aggressive lipid lowering does not improve endothelial function in type 2 diabetes: the Diabetes Atorvastatin Lipid Intervention (DALI) Study: a randomized, double-blind, placebo-controlled trial. Diabetes Care 25:1211-1216.
94. MAY, H.T., J.L. ANDERSON, R.R. PEARSON, J.R. JENSEN, B.D. HORNE, F. LAVASANI, H.D. YANNICELLI, and J.B. MUHLESTEIN. 2008. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). Am J Cardiol 101:486-489.
95. MUHLESTEIN, J.B., H.T.MAY, J.R. JENSEN, B.D. HORNE, R.B. LANMAN, F. LAVASANI, R.L.WOLFERT, R.R. PEARSON, H.D. YANNICELLI, and J.L. ANDERSON. 2006. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol 48:396-401.
96. BETTERIDGE, D.J. 2001. Lipid-lowering trials in diabetes. Curr Opin Lipidol 12:619-623.
97. UK, Prospective Diabetes Study, Group. 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703-713.
98. UK, Prospective Diabetes Study Group. 1998. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317:713-720.
99. BAIGENT, C., L. BLACKWELL, R. COLLINS, J. EMBERSON, J. GODWIN, R. PETO, J.BURING, C. HENNEKENS, P. KEARNEY, T.MEADE, C. PATRONO, M.C. RONCAGLIONI, and A. ZANCHETTI. 2009. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860.
100. BLOOMGARDEN, Z.T. 2008. Glycemic control in diabetes: a tale of three studies. Diabetes Care 31:1913-1919.
101. RAY, K.K., S.R. SESHASAI, S. WIJESURIYA, R. SIVAKUMARAN, S. NETHERCOTT, D. PREISS, S. ERQOU, and N. SATTAR. 2009. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765-1772.
102. SELVIN, E., S. BOLEN, H.C. YEH, C.WILEY, L.M.WILSON, S.S.MARINOPOULOS, L. FELDMAN, J.VASSY, R. WILSON, E.B. BASS, and F.L. BRANCATI. 2008. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168:2070-2080.
103. KAHN, S.E. 2009. Glucose control in type 2 diabetes: still worthwhile and worth pursuing. JAMA 301:1590-1592.
104. SJOLIE, A.K., R.KLEIN,M. PORTA, T. ORCHARD, J.FULLER, H.H. PARVING, R.BILOUS, and N. CHATURVEDI. 2008. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECTProtect 2): a randomised placebo-controlled trial. Lancet 372:1385-1393.
105. VORA, J.P., H.A. IBRAHIM, and G.L. BAKRIS. 2000. Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. J Hum Hypertens 14:667-685.
106. RAVID, M., D. BROSH, Z. LEVI, Y. BAR-DAYAN, D. RAVID, and R. RACHMANI. 1998. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982-988.
107. BACKONJA, M., A.BEYDOUN, K.R.EDWARDS, S.L. SCHWARTZ,V. FONSECA,M.HES, L. LAMOREAUX, and E. GAROFALO. 1998. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 280:1831-1836.
108. MAX, M.B., S.A. LYNCH, J. MUIR, S.E. SHOAF, B. SMOLLER, and R. DUBNER. 1992. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Engl J Med 326:1250-1256.
109. OSTGREN, C.J., U. LINDBLAD, A. MELANDER, and L. RASTAM. 2002. Survival in patients with type 2 diabetes in a Swedish community: Skaraborg Hypertension and Diabetes Project. Diabetes Care 25:1297-1302.
110. RIDKER, P.M., E. DANIELSON, F.A. FONSECA, J. GENEST, A.M. GOTTO, JR., J.J. KASTELEIN, W. KOENIG, P. LIBBY, A.J. LORENZATTI, J.G. MACFADYEN, B.G. NORDESTGAARD, J. SHEPHERD, J.T. WILLERSON, and R.J.GLYNN. 2008. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207.
111. AYALA, J.E., D.P. BRACY, F.D. JAMES, B.M. JULIEN, D.H. WASSERMAN, and D.J. DRUCKER. 2009. The glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action. Endocrinology 150:1155-1164.